Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/01/22
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC | NCT05363280 | Advenchen Pharmaceuticals, LLC. | user2@example.com | None | 2022-11-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |